ASX RELEASE

INVESTOR CONFERENCE CALL RECORDING

17 March 2017: Specialty pharmaceutical company, Race Oncology Ltd (ASX: RAC) is pleased to advise that a recording of the Investor Conference Call hosted on **Thursday, 16 March 2017** is now available at the following link: http://www.openbriefing.com/OB/2474.aspx

During the call Race Oncology CEO Peter Molloy provided an update on the important recent developments and the Company's plans for the coming year.

Further information can also be found in Race Oncology's updated Investor Presentation released on 9 March 2017.

About Race Oncology

Race Oncology Limited is a specialty pharmaceutical company, whose business model is to pursue later stage assets, principally in the cancer field. The Company's first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II clinical studies during the 1980s and 1990s. Race Oncology owns recent patent filings on Bisantrene and has secured Orphan Drug Designation in the US. The Company's goal is to complete final development of Bisantrene and bring this valuable cancer drug to market. Visit **raceoncology.com** for more information.

For more information, contact:

Peter Molloy T: +61 (0) 3 9097 1656
Managing Director E: investors@raceoncology.com

Investor Relations
F T I Consulting
T: +61 (0)8 9485 8888
E: Elodie.Castagna@fticonsulting.com / Steve.Suleski@fticonsulting.com